

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/atm-21-6899	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	
3	What data in particular will be shared?	The data of adverse events will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the adverse events may be followed again and updated over time.
7	To whom will you share the data?	Medical oncologists and clinical pharmacists who are interested in studies of PD-1 inhibitors.
8	For what type of analysis or purpose?	For analysis to evaluate the safety of PD-1 inhibitors in lung cancer patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: zhengxw@zjcc.org.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.